Through this series of six blogs, Dr. Richard Ablin, who discovered the PSA test, reveals for the first time, that the PSA test was never a prostate cancer test.
During the development of the PSA test decades ago, when did it become apparent to you that it was inaccurate at detecting prostate cancer?
Dr. Richard Ablin:
I discovered prostate-specific antigen (PSA) in 1970 while doing research on the prostate. It was during my studies that I realized that PSA is present in the normal, benign, and cancerous prostate. I knew soon after my discovery that PSA was not prostate cancer-specific; therefore, it does not detect prostate cancer.
Nine years later, researchers at Roswell Park Cancer Institute, led by Dr. T. Ming Chu, developed the basic PSA technology that ultimately was patented in 1984 and sold to a biotech company named Hybritech, which made and sold the PSA test kits. I discuss this in detail in my book. The profit-driven handoff of PSA technology from Roswell Park to Hybritech began one of the darkest periods in U.S. medical history.
The Germ That Causes Cancer
This book expounds upon the role of fungus in cancer. Most physicians are unaware that common antibiotics may contribute to cancer while drugs that kill fungus often help cancer patients. This is an important book that has been reduced to a much easier read for the layperson. It includes a chemotherapy nurses notes, the confessions of a chemotherapy drug salesman and a physicians account of what he would do if he were diagnosed with cancer.